Emend and Topotecan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emend (aprepitant) and Topotecan (topotecan hydrochloride). Common drug interactions include interstitial lung disease among females and skin disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Emend and Topotecan. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Topotecan?

Topotecan has active ingredients of topotecan hydrochloride. eHealthMe is studying from 5,853 Topotecan users. Check the latest studies of Topotecan.

On Jul, 10, 2026

25 people who take Emend and Topotecan together, and have interactions are studied.

What are the common drug interactions of Emend and Topotecan, by gender? *:

female:

Interstitial lung disease
Cough
Dyspnoea (difficult or laboured respiration)
Urinary tract infection
Atypical pneumonia (acute respiratory disease marked by high fever and coughing)
Blood calcium decreased
Blood glucose increased
Blood potassium decreased
Blood uric acid increased
C-reactive protein increased

male:

Skin disorder (skin disease)
Conjunctivitis (pink eye)
Ocular hyperaemia (an abnormally large amount of blood in eye)
Optic ischaemic neuropathy (optic nerve damage due to lack of blood supply)
Osteonecrosis of jaw (death of bone of jaw)
Rash
Abdominal pain
Anaemia (lack of blood)
Chest pain
Colitis (inflammation of colon)

What are the common drug interactions of Emend and Topotecan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Oesophagitis (inflammation of oesophagus)
Diarrhoea
Febrile neutropenia (fever with reduced white blood cells)
Stomatitis (inflammation of mucous membrane of mouth)

20-29:

n/a

30-39:

n/a

40-49:

Haematochezia (passage of stools containing blood)
Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
White blood cell count decreased
Death
Thrombocytosis
Urinary tract infection

50-59:

Haemorrhoids (a swollen vein or group of veins in the region of the anus)
Hyperkeratosis (thickening of the outer layer of the skin)
Ingrowing nail
Neuropathy peripheral (surface nerve damage)
Thrombocytopenia (decrease of platelets in blood)
Blindness
Eye pain
Ocular hyperaemia (an abnormally large amount of blood in eye)
Optic ischaemic neuropathy (optic nerve damage due to lack of blood supply)
Osteonecrosis of jaw (death of bone of jaw)

60+:

Interstitial lung disease
Abdominal pain
Anaemia (lack of blood)
Colitis (inflammation of colon)
Gastritis (inflammation of stomach)

What are the existing conditions these people have? *

Colon Cancer: 10 people, 40.00%
Nausea And Vomiting: 7 people, 28.00%
Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 4 people, 16.00%
Cervix Carcinoma (cancer of cervix): 3 people, 12.00%
Pain: 2 people, 8.00%
Ovarian Cancer (cancer of ovary): 2 people, 8.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 2 people, 8.00%
Gastric Ulcer (stomach ulcer): 2 people, 8.00%
Constipation: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and Topotecan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously